Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-07-17
2007-07-17
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C514S04400A, C435S320100
Reexamination Certificate
active
10748337
ABSTRACT:
A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified defective, diseased or damaged brain cells. Using a viral vector, the concentration of neurotrophin delivered as part of a neurotrophic composition varies from 1010to 1015neurotrophin encoding viral particles/ml of composition fluid. Each delivery site receives from 2.5 μl to 25 μl of neurotrophic composition, delivered slowly, as in over a period of time ranging upwards of 10 minutes/delivery site. Each delivery site is at, or within 500 μm of, a targeted cell, and no more than about 10 mm from another delivery site. Stable in situ neurotrophin expression can be achieved for 12 months, or longer.
REFERENCES:
patent: 5082670 (1992-01-01), Gage et al.
patent: 5529774 (1996-06-01), Barba et al.
patent: 5650148 (1997-07-01), Gage et al.
patent: 5683695 (1997-11-01), Shen et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5762926 (1998-06-01), Gage et al.
patent: 6451306 (2002-09-01), Tuszynski et al.
patent: 6683058 (2004-01-01), Tuszynski
patent: 6815431 (2004-11-01), Tuszynski
patent: WO 90/06757 (1990-06-01), None
Schinstine et al. (1995) Polymer-encapsulated Schwannoma cells expressing human nerve growth factor promote the survival of cholinergic neurons after a fimbria-fornix transection. Cell Transplant. 4:93-102.
Martinez-Serrano et al. (1995) CNS-Derived Neural Progenitor Cells for Gene Transfer of Nerve Growth Factor to the Adult Rat Brain:Complete Rescue of Axotomized Cholinergic Neurons after Transplantation into the Septum. 15:5668-5680.
Rogawski MA (2004) What is the rationale for new treatment strategies in Alzheimer's disease? CNS Spectr. 9:6-12.
Counts et al. Reduction of Cortical TrkA but not p75NTR protein in Early-Stage Alzheimer's disease. 56:520-531.
Verma et al., Gene therapy-promises, problems and prospects. (1997) Nature. 389:239-242.
Orkin et al., Report and Reccommendations of the Panel to assess the NIH invextment in Research on Gene Therapy (1998) 1-41.
Marshall., Gene Therapy's Growing Pains (1995) Science 269:1050-1055.
Reichardt et al. (2004) Going the distance, or not with neurotrophin signals. Cell. 118:141-143.
Pfeifer and Verma (2001) Annu. Rev. Genomics. Hum. Genet. 2:177-211.
Johnson-Saliba et al. (2001) Curr. Drug. Targets 2:371-99.
Shoji et al. (2004) Current Pharmaceutical Design 10 :785-796.
Armelin et al., “Pituitary extracts and steroid hormones in the control of 3T3 cell growth”Proc. Natl. Acad. Sci. (1973) 70:2702-6.
Banerji et al., “Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences”Cell(1981) 27:299-308.
Benoist et al., “In vivo sequence requirements of the SV40 early promoter region”Nature(1981) 290:304-10.
Blesch et al., “Ex vivo gene therapy for Alzheimer's disease and spinal cord injury”Clinical Neuroscience(1996) 3:268-274.
Borsani et al., “cDNA sequence of human beta-NGF”Nucleic Acids Res.(1990) 18:4020.
Breathnach et al., “Organization and expression of eucaryotic split genes coding for proteins”Ann. Rev. Biochem.(1981) 50:349-83.
Chen et al., “Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA”BioTechniques(1988) 6:632-8.
Chen et al., “High-efficiency transformation of mammalian cells by plasmid DNA”Mol. Cell. Biol.(1987) 7:2745-52.
Chua et al., “Tumor necrosis factor-alpha induces mRNA for collagenase and TIMP in human skin fibroblasts”Connect. Tissue Res.(1990) 25:161-170.
Conner et al., “Distribution of NGF delivered into the rat CNS by either grafted NGF-secreting fibroblasts, intraparenchymal (IP) injections, or IP-infusions”Society for Neuroscience(1997) 23:53 Abstract 29.5.
Corden et al., “Promoter sequences of eukaryotic protein-coding genes.”Science(1980) 209:1406-14.
DePamphilis et al., “Microinjecting DNA into mouse ova to study DNA replication and gene expression and to produce transgenic animals”BioTechniques(1988) 6:662-80.
de Wet et al., “The mRNAs for the pro-alpha 1(I) and pro-alpha 2(I) chains of type 1 procollagen are translated at the same rate in normal human fibroblasts and in fibroblasts from two variants of osteogenesis imperfecta with altered steady state ratios of the two mRNAs”J. Biol. Chem.(1983) 258:14385-9.
Elias et al., “Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma”Ann. N. Y. Acad. Sci.(1990) 580:233-244.
Felgner et al., “Cationic liposome mediated transfection”Proc. West. Pharmacol. Soc.(1989) 32:115-21.
Felgner et al., “Cationic liposome mediated transfection”Focus.(1989) 11:21-25.
Felgner et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure”Proc. Natl. Acad. Sci.(1987) 84:7413-7.
Fraley et al., “New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids”Trends Biochem. Sci.(1981) 6:77-80.
Fromm et al., “Deletion mapping of DNA regions required for SV40 early region promoter function in vivo”J. Mol. Appl. Genet.(1982) 1:457-81.
Gruss et al., “Simian virus 40 tandem repeated sequences as an element of the early promoter”Proc. Natl. Acad. Sci.(1981) 78:943-7.
Hefti et al., “Nerve growth factor and Alzheimer's disease”Ann. Neurol.(1986) 20:275-81.
Higgins et al., “NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease”Exp. Neurol.(1989) 106:222-36.
Horellou et al., “Adenovirus-mediated gene transfer to the central nervous system for Parkinson's Disease”Experimental Neurobiology(1997) 144:131-8.
Jolly et al., “Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene”Nucleic Acids Res.(1983) 11:1855-1872.
Kobayashi et al., “Morphometric study on the CH$ of the nucleus basalis of Meynert in Alzheimer's disease”Mol. Chem. Neuropathol.(1991) 15:193-206.
Kordower et al., “The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor”Proc. Natl. Acad. Sci.(1994) 91:10898-10902.
Lehericy et al., “Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease”J. Comp. Neurol.(1993) 330:15-31.
Levivier et al., “Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease”The Jo. Of Neuroscience(1995) 15:7810-20.
Mannino et al., “Liposome mediated gene transfer”Biotechniques(1988) 6:682-90.
Maxam et al., “Sequencing end-labeled DNA with base-specific chemical cleavages”Methods in Enzymology(1980) 65:499-560.
McCutchan et al., “Enhancement of the infectivity of simian virus 40 deoxy ribonucleic acid with diethylaminoethyl-dextran”J. Natl. Cancer Inst.(1968) 41:351-7.
Messing et al., “A system for shotgun DNA sequencing”Nucleic Acids Res.(1981) 9:309-21.
Mesulam et al., “Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey.”J. Comp. Neurol.(1983) 214:170-197.
Moreau et al., “The SV40 72 base repair repeat has a striking effect on gene expression bo
Crouch Deborah
DLA Piper (US) LLP
Regents of the University of California
LandOfFree
Methods for therapy of neurodegenerative disease of the brain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for therapy of neurodegenerative disease of the brain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for therapy of neurodegenerative disease of the brain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3769400